Lawyers Debate Degree Of Enforcement On Off-Label Promotion
This article was originally published in The Pink Sheet Daily
Executive Summary
Is the Justice Department skewing FDA policy priorities too much in the direction of heavy-handed off-label promotion enforcement? Attorneys debate.
You may also be interested in...
Louis Jacques On Coverage, Evidence And IDEs
Former CMS coverage director Louis Jacques talks about the strong future ahead he envisions for the Medicare coverage-with-evidence-development program and new coverage policies that will be implemented for investigational device exemption trials.
Reimbursement Briefs: Pfizer Joins Big Data Group; Part D Protected Classes; Wikipedia Partners With Cochrane Collaboration
Pfizer is among seven organizations joining the Optum Labs research collaborative; CMS Coverage and Analysis Group Director Louis Jacques moving to private sector, more news in brief.
Organogenesis Prepares To Restructure In The Face Of New CMS Skin-Substitute Policy
The maker of Apligraf for foot ulcers and venous leg ulcers is facing a more than 30% reduction in Medicare reimbursement starting Jan. 1. Organogenesis’ CEO says the firm is readying a plan to significantly trim its business costs so it can continue to market the PMA-approved, bioengineered product.